“Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients”, FE, vol. 15, no. 4, pp. 101–112, Dec. 2014, doi: 10.7175/fe.v15i4.971.